Shu Tian

973 total citations
21 papers, 743 citations indexed

About

Shu Tian is a scholar working on Oncology, Surgery and Otorhinolaryngology. According to data from OpenAlex, Shu Tian has authored 21 papers receiving a total of 743 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Surgery and 7 papers in Otorhinolaryngology. Recurrent topics in Shu Tian's work include Cancer Immunotherapy and Biomarkers (5 papers), Head and Neck Cancer Studies (5 papers) and Head and Neck Surgical Oncology (4 papers). Shu Tian is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Head and Neck Cancer Studies (5 papers) and Head and Neck Surgical Oncology (4 papers). Shu Tian collaborates with scholars based in China, Oman and United States. Shu Tian's co-authors include Jin Li, Liguang Lou, Haitian Quan, Fangfang Lü, Haiyi Guo, Chengying Xie, Yongping Xu, Weijian Guo, Lan Lin and Xianghuo He and has published in prestigious journals such as Nature Communications, Biochemical and Biophysical Research Communications and International Journal of Cancer.

In The Last Decade

Shu Tian

20 papers receiving 732 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shu Tian China 12 377 256 238 167 133 21 743
Catherine Park United States 8 380 1.0× 312 1.2× 210 0.9× 295 1.8× 213 1.6× 11 926
Yuezong Bai China 15 629 1.7× 402 1.6× 248 1.0× 268 1.6× 149 1.1× 60 987
E. Joosens Belgium 11 258 0.7× 173 0.7× 133 0.6× 72 0.4× 102 0.8× 26 587
Olga Venditti Italy 8 517 1.4× 204 0.8× 153 0.6× 117 0.7× 68 0.5× 26 786
Francis Parnis Australia 14 328 0.9× 457 1.8× 186 0.8× 160 1.0× 112 0.8× 60 761
Pierre Bohanes United States 16 592 1.6× 266 1.0× 350 1.5× 205 1.2× 213 1.6× 52 1.0k
Akira Ooki Japan 20 617 1.6× 456 1.8× 595 2.5× 303 1.8× 331 2.5× 98 1.4k
L. Kayitalire France 17 745 2.0× 453 1.8× 163 0.7× 160 1.0× 173 1.3× 40 1.1k
Sylvie Job France 17 417 1.1× 493 1.9× 434 1.8× 457 2.7× 376 2.8× 23 1.1k
Jia Luo United States 15 528 1.4× 458 1.8× 328 1.4× 288 1.7× 97 0.7× 64 1.0k

Countries citing papers authored by Shu Tian

Since Specialization
Citations

This map shows the geographic impact of Shu Tian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu Tian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu Tian more than expected).

Fields of papers citing papers by Shu Tian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shu Tian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu Tian. The network helps show where Shu Tian may publish in the future.

Co-authorship network of co-authors of Shu Tian

This figure shows the co-authorship network connecting the top 25 collaborators of Shu Tian. A scholar is included among the top collaborators of Shu Tian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu Tian. Shu Tian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Gong, Hongli, Shu Tian, Lei Tao, et al.. (2024). Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial. Nature Communications. 15(1). 5251–5251. 12 indexed citations
4.
Zhang, Yujie, Qingsong Wang, Jiong Zhang, et al.. (2024). Study on carbon footprint evaluation and carbon reduction path of cross-basin water transfer project – A case study of the Yellow River East diversion project in China. Environmental Impact Assessment Review. 106. 107509–107509. 11 indexed citations
5.
Tian, Shu, et al.. (2023). Increased response to TPF chemotherapy promotes immune escape in hypopharyngeal squamous cell carcinoma. Frontiers in Pharmacology. 13. 1097197–1097197. 2 indexed citations
6.
Wang, Mei, et al.. (2022). Management and prevention of brachial plexus injury caused by surgical suture of neck dissection induced chylous fistula. American Journal of Otolaryngology. 43(5). 103597–103597. 3 indexed citations
7.
8.
Liu, Chuanxu, Hao Ding, Qi Zhu, et al.. (2022). Induction with MEDA regimen and consolidation with Auto‐HSCT for stage IV NKTCL patients: A prospective multicenter study. International Journal of Cancer. 151(5). 752–763. 5 indexed citations
9.
10.
Tian, Shu, Qin Li, Xinyu Chen, et al.. (2021). Development and Validation of a Prognostic Nomogram for Hypopharyngeal Carcinoma. Frontiers in Oncology. 11. 696952–696952. 20 indexed citations
11.
Zhu, Yang, Shu Tian, Lan Xu, et al.. (2021). GELAD chemotherapy with sandwiched radiotherapy for patients with newly diagnosed stage IE/IIE natural killer/T‐cell lymphoma: a prospective multicentre study. British Journal of Haematology. 196(4). 939–946. 7 indexed citations
12.
13.
Hu, Chunyan, et al.. (2020). Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma. Oral Oncology. 102. 104560–104560. 21 indexed citations
14.
Yang, Yan, Zhaoyang Wang, Shu Tian, et al.. (2020). miR-7641 depletion suppresses proliferation of gastric cancer cells by targeting ARID1A. Anti-Cancer Drugs. 31(4). 368–376. 14 indexed citations
15.
16.
Tian, Shu, et al.. (2019). Comparative outcome of surgical and nonsurgical therapy for T4bN0M0 sinonasal squamous cell carcinomas. European Archives of Oto-Rhino-Laryngology. 276(11). 3113–3122. 16 indexed citations
17.
Tian, Shu, et al.. (2019). Management of orbital invasion in esthesioneuroblastoma: 14 years’ experience. Radiation Oncology. 14(1). 107–107. 17 indexed citations
18.
Tian, Shu, Haitian Quan, Chengying Xie, et al.. (2011). YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Science. 102(7). 1374–1380. 436 indexed citations
19.
Liu, Xin, Weijian Guo, Xiao-Wei Zhang, et al.. (2011). Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan. Cancer Chemotherapy and Pharmacology. 68(4). 871–878. 22 indexed citations
20.
Tian, Shu, Shenglin Huang, Shun‐Quan Wu, et al.. (2010). MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3′ untranslated region. Biochemical and Biophysical Research Communications. 396(2). 435–439. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Park Breakdown of academic impact, for papers by Yuezong Bai Breakdown of academic impact, for papers by E. Joosens Breakdown of academic impact, for papers by Olga Venditti Breakdown of academic impact, for papers by Francis Parnis Breakdown of academic impact, for papers by Pierre Bohanes Breakdown of academic impact, for papers by Akira Ooki Breakdown of academic impact, for papers by L. Kayitalire Breakdown of academic impact, for papers by Sylvie Job Breakdown of academic impact, for papers by Jia Luo
Rankless by CCL
2026